Literature DB >> 10335742

The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and cross-validation of scoring algorithms.

J E Ware1, S D Keller, H T Hatoum, S X Kong.   

Abstract

An arthritis-specific health index (ASHI) for the SF-36 Health Survey was developed by studying its responsiveness to changes in clinical indicators of arthritis severity. Longitudinal data from 1,076 patients participating in four placebo-controlled trials were analyzed. All had at least a 6-month history of moderate to severe osteoarthritis or rheumatoid arthritis of the knee or hip. All had undergone a washout period of 3 to 14 days before baseline assessment to bring about a flare state in osteoarthritis or rheumatoid arthritis symptoms. Their average age was 60 years and 72% were female. Change scores for the eight-scale SF-36 health profile (acute version) and five arthritis-specific measures of disease severity (knee pain on weight bearing, time to walk 50 feet, physician global evaluation of symptom severity and impact, patient global evaluation of symptom severity and impact, and pain intensity visual analogue scale) were computed by subtracting scores before treatment from scores at two-week follow-up. Canonical correlation methods were used to derive weights for changes in SF-36 scales to score a single index (ASHI) that maximized its correlation with changes in the set of five clinical measures of arthritis severity. The weights used to score the ASHI were cross-validated in a 25% holdout group (N = 144) from the first two osteoarthritis trials and in two additional osteoarthritis and rheumatoid arthritis trials (N = 530). Only one SF-36 canonical variate (ASHI) correlated significantly (F = 4.69, P < 0.0001) with the clinical canonical variate that served as the "criterion" measure of change in the severity of arthritis. Changes in the ASHI and clinical canonical variate were substantially correlated in the developmental sample (r = 0.628, P < 0.0001) and on cross-validation (r = 0.629, P < 0.0001). The clinical canonical variate correlated highly (r = 0.75-0.88) with changes in all but one of the five clinical measures (50-foot walk; r = 0.41). The pattern of correlations between changes in SF-36 scales and the ASHI indicated that ASHI is primarily a measure of bodily pain (r = 0.92) and other aspects of physical and role functioning and well-being (r = 0.69 for Role-Physical, r = 0.68 for Physical Functioning, r = 0.52 for Social Functioning, and r = 0.51 Vitality). The patterns of correlations between SF-36 scales and the ASHI were very similar across developmental and cross-validation samples. This research demonstrates the feasibility and generalizability of a single ASHI scored from changes in responses to the SF-36 Health Survey. The generic SF-36 health profile, which has already been shown to be useful in comparing arthritis with other diseases and treatments, can also be scored specifically to make it more useful in studies of osteoarthritis and rheumatoid arthritis.

Entities:  

Mesh:

Year:  1999        PMID: 10335742     DOI: 10.1097/00005650-199905001-00004

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  19 in total

Review 1.  Osteoarthritis.

Authors:  L S Simon
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

2.  Effects of Action Observation Therapy in Patients Recovering From Total Hip Arthroplasty Arthroplasty: A Prospective Clinical Trial.

Authors:  Jorge Hugo Villafañe; Caterina Pirali; Maria Isgrò; Carla Vanti; Riccardo Buraschi; Stefano Negrini
Journal:  J Chiropr Med       Date:  2016-10-05

3.  Extending the floor and the ceiling for assessment of physical function.

Authors:  James F Fries; Bharathi Lingala; Liseth Siemons; Cees A W Glas; David Cella; Yusra N Hussain; Bonnie Bruce; Eswar Krishnan
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

4.  Aging and physical function in type 2 diabetes: 8 years of an intensive lifestyle intervention.

Authors:  W Jack Rejeski; George A Bray; Shyh-Huei Chen; Jeanne M Clark; Mary Evans; James O Hill; John M Jakicic; Karen C Johnson; Rebecca Neiberg; Edward H Ip
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-07-01       Impact factor: 6.053

5.  Lifestyle change and mobility in obese adults with type 2 diabetes.

Authors:  W Jack Rejeski; Edward H Ip; Alain G Bertoni; George A Bray; Gina Evans; Edward W Gregg; Qiang Zhang
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

Review 6.  Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review.

Authors:  M B Nichol; A S Harada
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

7.  PRO development: rigorous qualitative research as the crucial foundation.

Authors:  Kathryn Eilene Lasch; Patrick Marquis; Marc Vigneux; Linda Abetz; Benoit Arnould; Martha Bayliss; Bruce Crawford; Kathleen Rosa
Journal:  Qual Life Res       Date:  2010-05-30       Impact factor: 4.147

8.  Validation of the Portuguese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-41) in Brazilian women with postmenopausal osteoporosis with vertebral fracture.

Authors:  Néville de Oliveira Ferreira; Michael Arthuso; Raimunda Beserra da Silva; Aarão Mendes Pinto-Neto; Lúcia Costa-Paiva
Journal:  Clin Rheumatol       Date:  2013-04-23       Impact factor: 2.980

Review 9.  Pursuit of optimal outcomes in rheumatoid arthritis.

Authors:  David L Scott
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 10.  Patient-reported outcomes and their role in the assessment of rheumatoid arthritis.

Authors:  Deborah P Lubeck
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.